Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3389934 in Healthy Japanese Participants
NCT07176728Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BAY3389934 in disseminated intravascular coagulation (DIC) (3 arms), sponsored by Bayer. Primary endpoint: Treatment-Emergent Adverse Events at 5 weeks. Started Sep 2025; status: completed.
02
Drugs
BAY3389934
03
Conditions
disseminated intravascular coagulation (DIC)
Beyond the preview
Go deeper on NCT07176728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176728.